Research Use Disclaimer

You must be 21 or older. Agree to the following terms before accessing product information and pricing.

Research Use Policy Summary

You are 21 years of age or older
All products sold exclusively for laboratory research purposes
Products are not intended for human consumption, diagnosis, or therapeutic use
Purchasers must be qualified researchers or licensed professionals
These products have not been evaluated or approved by the FDA
All sales are final and subject to our research use terms

For laboratory research use only. Not for human or veterinary consumption, diagnostic use, therapeutic use, or clinical use.

Read full Research Use Disclaimer (opens in new tab) →

Product Usage Notice · This product is intended strictly for research and laboratory use only. It is designated for in vitro testing and experimental purposes. Any use involving human or animal consumption is prohibited by law. All information provided on this website is for educational purposes only. This product must only be handled by licensed, qualified professionals. It is not intended for use as a drug, food, or cosmetic, and must not be misused, mislabeled, or misrepresented as such. Read full Research Use Policy →

Compound Information

Technical specifications

Molecular Profile

What Is CJC-1295 No DAC?

CJC-1295 without DAC (also known as Modified GRF 1-29) is a truncated GHRH analog with four amino acid substitutions for improved stability, used in research on pulsatile growth hormone release.

Type: Peptide
CAS Number: 863288-34-0
Molecular Weight: 3367.95 g/mol
Amino Acids: 29 residues
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
Formula: C152H252N44O42

PubChem Database

CJC-1295 · 2006

Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295 in endocrine receptor pharmacology literature Journal of Endocrinology & Metabolism Published pharmacology literature examining CJC-1295 GH axis signaling mechanisms. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study

CJC-1295 · 2007

Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295 Journal of Endocrinology & Metabolism Published pharmacology literature examining GH pulsatility preservation mechanisms. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study

CJC-1295 · 2009

Activation of the GH/IGF-1 Axis by CJC-1295 in endocrine receptor pharmacology literature Growth Hormone & IGF Research Proteomic analysis describing GH/IGF-1 axis pathway markers following CJC-1295 exposure. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study

CJC-1295 · 2006

CJC-1295, a Long-Acting GHRH Analog, and GH/IGF-1 Axis Signaling in endocrine receptor pharmacology literature Journal of Endocrinology & Metabolism Published pharmacology literature examining long-acting GHRH analog receptor signaling. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study

CJC-1295 · 2012

Combination of GHRH Analog with GHRP Achieves Synergistic GH Release Journal of Endocrinology & Metabolism Published study examining synergistic GH axis receptor engagement when combining GHRH and GHRP mechanisms. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study

CJC-1295 · 2007

Growth Hormone-Releasing Hormone in published pharmacology Practice: Focus on Long-Acting Analogs Endocrinology and Metabolism Clinics of North America Published review examining CJC-1295 pharmacokinetics including albumin-binding half-life extension and IGF-I axis modulation. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study